Advertisement

Literaturverzeichnis

  • Hans-Peter Volz
Chapter
  • 13 Downloads
Part of the DUV: Medizin book series (DUVM)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literaturverzeichnis

  1. 1.
    Ansseau M, Papart P, GÉRard MA, Frenckell R Von, Franck G. Controlled comparison of buspirone and oxazepam in generalized anxiety. Neuropsychobiology 1990; 24: 74–78.PubMedCrossRefGoogle Scholar
  2. 2.
    Ashron CH, Rawlins MD, Tyrer SP. A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry 1990; 157: 232–238.CrossRefGoogle Scholar
  3. 3.
    Bakish D. Fluoxetine potentiation by buspirone: three case histories. Can J Psychiatry 1991; 36: 749–750.PubMedGoogle Scholar
  4. 4.
    Balster RL. Abuse potential of buspirone and related drugs. J Clin Psychopharmacol 1990; 10 (suppl 3): 31S - 37S.PubMedCrossRefGoogle Scholar
  5. 5.
    Balster RL. Preclinical studies of the abuse potential of buspirone. Aus: Tunnicliff G, et al. (eds.). Buspirone: Mechanisms and Clinical Aspects. San Diego etc.: Academic Press 1991: 97–107.Google Scholar
  6. 6.
    Barbanoj MJ, Anderer P, Antonijoan RM, Torrent J, Saletu B, Jane F. Topographic pharmaco-Eeg mapping of increasing doses of buspirone and its comparison with diazepam. Human Psychopharmacology 1990; 9: 101–109.CrossRefGoogle Scholar
  7. 7.
    Barbanoj MJ, Antonijoan RM, Jane F. Buspirone and electroencephalography (letter). Clin Pharmacol Ther 1995; 57: 699.PubMedCrossRefGoogle Scholar
  8. 8.
    Barbhaija RH, Shukla UA, Pfeffer M, Pittman KA, Shrotriya R, Laroudie C, Gammans RE. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur J Clin Pharmacol 1994; 46: 41–47.Google Scholar
  9. 9.
    Baughman OL. The safety record of buspirone in generalized anxiety disorder. J Clin Psychiatry Monograph 1994; 12 (1): 37–43.Google Scholar
  10. 10.
    BÖHM C, Placchi M, Stallone F, Gammans RE, Alms DR, Shrotriya RC, Robinson DS. A double-blind comparison of buspirone, clobazam, and placebo in patients with anxiety treated in a general practice setting. J Clin Psychopharmacol 1990; 10 (suppl 3): 38S - 42S.PubMedCrossRefGoogle Scholar
  11. 11.
    BÖHM C, Robinson DS, Gammans RE, Shrotriya RC, Alms DR, Leroy A, Placchi M. Buspirone therapy in anxious elderly patients: A controlled clinical trial. J Clin Psychopharmacol 1990; 10 (suppl 3): 47S - 51S.PubMedCrossRefGoogle Scholar
  12. 12.
    Boral GC, Bandopadhaya G, Oke VK, Jha RJ, Navani SR, Bowalekar SK, Raghu CN. Double-blind, randomized clinical evaluation of buspirone and diazepam in generalized anxiety disorders. Advances in Therapy 1989; 6: 112–124.Google Scholar
  13. 13.
    Boulenger JP, Squillace K, Simon P, Herrou M, Leymarie P, Zarifian E. Buspirone and diazepam: comparison of subjective, psychomotor and biological effects. Neuropsychobiology 1989; 22: 83–89.PubMedCrossRefGoogle Scholar
  14. 14.
    Boylan K. Persistent dystonia associated with buspirone. Neurology 1990; 40: 1904.PubMedCrossRefGoogle Scholar
  15. 15.
    Brown CS, Ling FW, Farmer RG, Stone BF. Buspirone in the treatment of premenstrual syndrome. Drug Therapy Suppl. August: 1990; 112–115.Google Scholar
  16. 16.
    Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology 1989; 22 (suppl 1): 49–59.PubMedCrossRefGoogle Scholar
  17. 17.
    Buchheim P, Bender W, Greil W, Scheibe G. Buspiron versus Lorazepam–eine dreiwöchige Doppelblindstudie bei ambulanten Patienten mit Angstsyndromen. Aus: Hippius H (Hrsg.). Buspiron-Workshop. Expertengespräch Gstaad, 12.-14. April 1984. Gräfelfing: Sociomedico, 1985: 89–103.Google Scholar
  18. 18.
    Bullen WW, Bivens DL, Gammans RE, Labudde LA. The binding of buspirone to human plasma proteins. Federation Proceedings 1985; 44: 1123.Google Scholar
  19. 19.
    Caccia S, Fong MH, Guiso G. Disposition of the psychotropic drugs buspirone, MJ-13805 and piribedil, and of their common active metabolite 1-(2-pyrimidinyl)-piperazine in the rat. Xenobiotica 1985; 15: 835–844.PubMedCrossRefGoogle Scholar
  20. 20.
    Caccia S, Vigano GL, Mingardi G, Garattini S, Gammans RE, Placchi M, Mayol RF, Pfeffer M. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clin Pharmacokin 1988; 14: 171–177.CrossRefGoogle Scholar
  21. 21.
    Ciraulo DA, Barnhill JG, Ciraulo AM, Greenblatt DJ, Shader RI. Parental alcoholism as a risk factor in benzodiazepine abuse: a pilot study. Am J Psychiatry 1989; 146: 1333–1335.PubMedGoogle Scholar
  22. 22.
    Coccaro EF, Gabiriel S, Siever LJ. Buspirone challenge: preliminary evidence for a role for central 5-HT,A receptor function in impulsive aggressive behaviour in humans. Psychopharmacol Bull 1990; 26: 393–405.PubMedGoogle Scholar
  23. 23.
    Cohn JB, Bowden CL, Fisher JG, RoDos JJ. Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med 1986a; 80 (suppl 3B): 10–16.PubMedCrossRefGoogle Scholar
  24. 24.
    Cohn JB, Wilcox CS, Meltzer HY. Neuroendocrine effects of buspirone in patients with generalized anxiety disorder. Am J Med 1986b; 80 (suppl 3B): 36–40.PubMedCrossRefGoogle Scholar
  25. 25.
    Cohn JB, WiLcox CS. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study. J Clin Psychiatry 1986c; 47: 409–412.PubMedGoogle Scholar
  26. 26.
    Cohn JB, Rickels K. A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety. Curr Med Res Opin 1989; 11: 304–320.PubMedCrossRefGoogle Scholar
  27. 27.
    Cole JO, Orzack MH, Beake B, Bird M, Bar-Tal Y. Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry 1982; 43: 69–74.PubMedGoogle Scholar
  28. 28.
    Colenda CC. Buspirone in treatment of agitated demented patient [letter]. Lancet 1988; 1: 1169.PubMedCrossRefGoogle Scholar
  29. 29.
    Colella RF, Ratey JJ, Glaser Al. Paramenstrual aggression in mentally retarded adult ameliorated by buspirone. Int J Psychiatry Med 1992; 22: 351–356.PubMedGoogle Scholar
  30. 30.
    Collins DM, Myers RD. Buspirone attenuates volitional alcohol intake in the chronically drinking monkey. Alcohol 1987; 4: 49–56.PubMedCrossRefGoogle Scholar
  31. 31.
    Cowen PJ, Anderson IM, Grahame-Smith DG. Neuroendocrine effects of azapirones. J Clin Psychopharmacol 1990; 10 (suppl 3): 21S - 25S.PubMedCrossRefGoogle Scholar
  32. 32.
    Craven J, Southerland A. Buspirone for the anxiety disorder in patients with severe lung disease. Lancet 1991; 338: 249.PubMedCrossRefGoogle Scholar
  33. 33.
    DelleChiaie R, Pancheri P, Casacchia M, Stratta P, Kotzalidis GD, Zibellini M. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. Clin Psychopharmacol 1995; 15: 12–19.CrossRefGoogle Scholar
  34. 34.
    Dement WC, Seidel WF, Cohen SA, Bailey R, Rountree M, Yost D. Effects of alprazolam, buspirone and diazepam on daytime sedation and performance. Drug Invest 1991; 3: 148–156.CrossRefGoogle Scholar
  35. 35.
    Dilling H, Mombour W, Schmidt MH, Schulte-Markwort E (Hrsg.). Internationale Klassifikation psychischer Störungen. Icd-10 Kapitel V ( F). Forschungskriterien. Bern etc.: Huber 1994.Google Scholar
  36. 36.
    Dinan TG, Barry S, Yatham LN, Mobayed M, O’Hanlon M. The reproducibility of the prolactin response to buspirone: relationship to menstrual cycle. Int Clin Psychopharmacol 1990; 5: 119–123.PubMedCrossRefGoogle Scholar
  37. 37.
    Domantay AG, Napoliello MJ. Buspirone for elderly anxious patients: a review of clinical studies. Family Practice Recertification 1989; 11 (suppl 9): 17–23.Google Scholar
  38. 38.
    Eison MS, Eison AS. Buspirone as a midbrain modulator: anxiolysis unrelated to traditional benzodiazepine mechanisms. Drug Develop Res 1984; 4: 109–119.CrossRefGoogle Scholar
  39. 39.
    Eison AS, Eison MS, Stanley M, Riblet LA. Serotonergic mechanisms in the behavioural effects of buspirone and gepirone. Pharm and Biomed Behav 1986a; 24: 701–707.CrossRefGoogle Scholar
  40. 40.
    Eison AS, Temple DL. Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am J Med 1986b; 80 (suppl 3B): 1–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Eison AS. Azapirones: history of development. J Clin Psychopharmacol 1990; 10 (suppl 3): 25–55.Google Scholar
  42. 42.
    Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 1991; 105: 428–432.PubMedCrossRefGoogle Scholar
  43. 43.
    Erwin CW, Linnoila M, Hartwell J, Erwin A, Guthrie S. Effects of buspirone and diazepam, alone and in combination with alcohol, on skilled performance and evoked potentials. J Clin Psychopharmacol 1986; 6: 199–209.PubMedCrossRefGoogle Scholar
  44. 44.
    Fabre LE. Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatry 1990; 51 (suppl 9): 55–61.PubMedGoogle Scholar
  45. 45.
    Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 1982; 43 (section 2): 103–107.PubMedGoogle Scholar
  46. 46.
    Feighner JP. Buspirone in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 1987; 48 (suppl 12): 3–6.PubMedGoogle Scholar
  47. 47.
    Feighner JP, Cohn JB. Analysis of individual symptoms in generalized anxiety–a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology 1989; 21: 124–130.PubMedCrossRefGoogle Scholar
  48. 48.
    Findling RL. Treatment of aggression in juvenile-onset Huntington’s disease with buspirone [letter]. Psychosomatics 1993; 34: 460–461.PubMedCrossRefGoogle Scholar
  49. 49.
    Fontaine R, Beaudry P, Beauclair L, Chouinard G. Comparison of withdrawal of buspirone and diazepam: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 1987; 11: 189–197.PubMedCrossRefGoogle Scholar
  50. 50.
    Friedman R. Possible induction of psychosis by buspirone. Am J Psychiatry 1991; 148: 1606.PubMedGoogle Scholar
  51. 51.
    Gammans RE, Mayol RF, Mackenthun AV, Soyka LF. The relationship between buspirone bioavailability and dose in healthy subjects. Biopharm Drug Dispos 1985; 6: 139–145.PubMedCrossRefGoogle Scholar
  52. 52.
    Gammans RE, Mayol RF, Labudde JA. Metabolism and disposition of buspirone. Am J Med 1986; 80 (suppl 3B): 41–51.PubMedCrossRefGoogle Scholar
  53. 53.
    Gammans RE, Westrick ML, Shea JP, Mayol RF, Labudde JA. Pharmacokinetics of buspirone in elderly patients. J Clin Pharmacol 1989; 29: 72–78.PubMedCrossRefGoogle Scholar
  54. 54.
    Gammans RE, Johnston RE. Metabolism, pharmacokinetics, and toxicology of buspirone. Aus: Tunnicliff G, et al. (eds.). Buspirone: Mechanisms and Clinical Aspects. San Diego etc.: Academic Press 1991; 233–260.Google Scholar
  55. 55.
    Gammans RE, Stringfellow JC, Hvizdos AJ, Seidehamel RJ, Cohn JB, Wilcox CS, Fabre LF, Pecknold JC, Smith WT, Rickels K. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. Neuropsychobiology 1992; 25: 193–201.PubMedCrossRefGoogle Scholar
  56. 56.
    Garner SJ, Eldridge FL, Wagner PG, Dowell RT. Buspirone: an anxiolytic drug that stimulates respiration. Am Rev Respir Dis 1989; 139: 946–950.PubMedCrossRefGoogle Scholar
  57. 57.
    Goetz CM, Krenzelok EP, Lopez G, Borys D. Buspirone toxicity: a prospective study. Annals of Emergency Medicine 1990; 19 (6): 630.CrossRefGoogle Scholar
  58. 58.
    Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 1991; 11: 193–197.PubMedGoogle Scholar
  59. 59.
    Goldberg HL, Finnerty R. Comparison of buspirone in two separate studies. J Clin Psychiatry 1982; 43 (section 2): 87–91.PubMedGoogle Scholar
  60. 60.
    Goodman WK, Mcdongle CJ, Barr LC, Aronson SC, Price LH. Biological approaches to treatment resistant obsessive compulsive disorder. J Clin Psychiatry 1993; 54 (suppl 6): 16–26.PubMedGoogle Scholar
  61. 61.
    Grady TA, Pigott TA, L’Heureux F, Hill JL, Bernstein SE, Murphy DL. Double-blind study of adjuvant buspirone for fluoxetinetreated patients with obsessive-compulsive disorder. Am J Psychiatry 1993; 150: 819–821.PubMedGoogle Scholar
  62. 62.
    Griffith HL, Jasinki DR, Casten GP, Mckinney GR. Investigation of the abuse liability of buspirone in alcohol-dependent patients. Am J Med 1986; 80 (suppl 3B): 30–35.PubMedCrossRefGoogle Scholar
  63. 63.
    Gualtieri CT. Buspirone for the behavior problems of patients with organic brain disorders [letter]. J Clin Psychopharmacol 1991; 11: 280–281.PubMedCrossRefGoogle Scholar
  64. 64.
    HallstrÖM C, Cox J. Rapid response to buspirone: assessment in a general practice setting. Br J Clin Res 1991; 2: 65–80.Google Scholar
  65. 65.
    Hargrave R. Serotonergic agents in the management of dementia and posttraumatic stress disorder [letter]. Psychosomatics 1993; 34: 461–462.PubMedCrossRefGoogle Scholar
  66. 66.
    Herrmann N, Eryavec G. Buspirone in the management of agitation and aggression associated with dementia. Am J Geriatric Psychiatry 1993; 1: 249–253.CrossRefGoogle Scholar
  67. 67.
    Hruban Z, Slesers A, Aschenbrenner I. Pulmonary intraalveolar histiocytosis induced by drugs. Toxicol Appl Pharmacol 1973; 26: 72–85.PubMedCrossRefGoogle Scholar
  68. 68.
    Iruela LM, Ibanez-Rojo V, Caballero L, Baca E. Buspirone-induced mania: possible interaction with disulfiram. Br J Psychiatry 1991; 159: 297–298.PubMedCrossRefGoogle Scholar
  69. 69.
    Jacobson AF, Dominguez RA, Goldstein BJ, Steinbook RM. Comparison of buspirone and diazepam in generalized anxiety disorder. Pharmacotherapy 1985; 5: 290–296.PubMedGoogle Scholar
  70. 70.
    Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991; 52: 217–220.PubMedGoogle Scholar
  71. 71.
    Jajoo HK, Mayol RF, Labudde JA, Blair IA. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 1989; 17: 634–640.PubMedGoogle Scholar
  72. 72.
    Jann MJ, D’SouzA MJ, Pollock SH. Ciclosporine/buspirone interaction. Eur J Pharmacol 1990; 183: 2296.Google Scholar
  73. 73.
    Jann MW, Froemming JH, Borrison RL. Movement disorders and new azapirones anxiolytic drugs. J Am Board Fam Pract 1990; 3: 111–119.PubMedGoogle Scholar
  74. 74.
    Jenike MA, Baer L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. J Clin Psychiatry 1991; 52: 13–14.PubMedGoogle Scholar
  75. 75.
    Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993; 54: 269–271.PubMedGoogle Scholar
  76. 76.
    Kahn RS, VanPraag HM, Wetzler S, Anis GM, Barr G. Serotonin and anxiety revisited. Biol Psychiatry 1988; 23: 189–208.PubMedCrossRefGoogle Scholar
  77. 77.
    Karabelnick D, Zbinden G, Baumgartner E. Drug-induced foam cell reaction in rats. I. Histologic and cytochemical observations after treatment with chlophenteramine, Rmi 10.393 and Ro 44318. Toxicol Appl Pharmacol 1974; 27: 395–407.Google Scholar
  78. 78.
    Kiev A, Domantay AG. A Study of Buspirone coprescribed with bronchodilatators in 82 anxious ambulatory patients. J Asthma 1988; 25 (suppl 5): 281–284.PubMedCrossRefGoogle Scholar
  79. 79.
    Kiev A, Domantay AG. A study of buspirone coprescribed with nonsteroidal antiinflammatory drugs in 150 anxious ambulatory patients. Curr Ther Res 1989; 46: 1086–1090.Google Scholar
  80. 80.
    Laakmann G, Breull A; Kriszio B. Buspirone treatment in anxious outpatients. 17th Cinp, Kyoto 1990; I: 174 (Abstract).Google Scholar
  81. 81.
    Laakmann G, Baghai T, Daffner-Bujia C, Kuhn K, Haag C, Becker U, Neuhauser H, Knossalla A. Influence of methysergide on the buspirone-induced prolactin, growth hormone, and cortisol stimulation in healthy subjects (letter). Hum Psychopharmacology 1995; 10: 489–492.Google Scholar
  82. 82.
    Laar MW Van, Volkerts ER, Willigenburg AP Van. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol 1992; 12: 86–95.PubMedGoogle Scholar
  83. 83.
    Lader MH. Long-term anxiolytic therapy: the issue of drug withdrawal. J Clin Psychiatry 1987a; 48 (suppl 12): 12–16.PubMedGoogle Scholar
  84. 84.
    Lader MH. Assessing the potential for buspirone dependence or abuse and effects of its withdrawal. Am J Med 1987b; 82 (suppl 5A): 20–26.PubMedCrossRefGoogle Scholar
  85. 85.
    Lader MH, Olajide D. A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. J Clin Psychopharmacol 1987c; 7: 11–15.PubMedCrossRefGoogle Scholar
  86. 86.
    Lader MH, Napoliello MJ. A Study of buspirone coprescribed with antihistamines in 68 anxious ambulatory patients. J Clin Psychopharmacol 1988; 8 (suppl 2): 146–148.PubMedCrossRefGoogle Scholar
  87. 87.
    Lang YH, Yang CY, Grice HC. Multifocal histiocytosis in the lungs of rats. J Pathol Bacteriol 1966; 27: 559–561.Google Scholar
  88. 88.
    Levine AM. Buspirone and agitation in head injury. Brain Inj 1988; 2: 165–167.PubMedCrossRefGoogle Scholar
  89. 89.
    Levine S, Napoliello MJ. A study of buspirone coprescribed with histamine H2-receptor antagonists in anxious outpatients. Int Clin Psychopharmacol 1988; 3: 83–86.PubMedCrossRefGoogle Scholar
  90. 90.
    Levine S, Napoliello MJ, Domantay AG. An open study of buspirone in octogenarians with anxiety. Hum Psychopharmacol 1989; 4: 51–53.CrossRefGoogle Scholar
  91. 91.
    Levy M, Burgio L, Davis P, Sweet R, Janoski J. Buspirone for disruptive behavior in community dwelling patients with dementia. 49th Annual Meeting of the American Geriatric Society, SA 3; 1992.Google Scholar
  92. 92.
    Ludwig CL, Weinberger DR, Bruno G, Gillespie M, Bakker K, Lewitt PA, Chase TN. Buspirone, Parkinson’s Disease and the locus ceruleus. Clin Neuropharmacol 1986; 9: 373–378.PubMedCrossRefGoogle Scholar
  93. 93.
    Maelen CP VanDer, Matheson GK, Wilderman RC, Patterson LA. Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a nonbenzodiazepine anxiolytic drug. Eur J Pharmacol 1986; 129: 123–130.CrossRefGoogle Scholar
  94. 94.
    Markovitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 1990; 147: 798–800.PubMedGoogle Scholar
  95. 95.
    Mattila MJ, Aranko K, SeppÄLÄ T. Acute effects of buspirone and alcohol on psychomotor skills. J Clin Psychiatry 1982; 43 (section 2): 56–60.PubMedGoogle Scholar
  96. 96.
    Mayol RF, Gammans RE, Mackenthun AV, Soyka LE The effect of food on the bioavailability of buspirone Hci. Clin Res 1983; 31: 631 A.Google Scholar
  97. 97.
    Mayol RF, Adamson DS, Gammans RE, LA Budde JA. Pharmacokinetics and distribution of 14C-buspirone Hci after intravenous and oral dosing in man. Clin Pharmacol Ther 1985; 37: 210.Google Scholar
  98. 98.
    McGowan G, Napoliello M, Alms D. Buspirone for the management of anxiety in patients with concomitant medical conditions: a retrospective preliminary evaluation. Curr Therapeutics 1988; 43: 481–486.Google Scholar
  99. 99.
    Mcmillen BA, Scorr SM, Davanzo EA. Reversal of neurolepticinduced catalepsy by novel aryl-piperazine anxiolytic drugs. J Pharm Pharmacol 1988; 40: 885–887.PubMedCrossRefGoogle Scholar
  100. 100.
    Moon SL, Taylor DP. In vivo autoradiography of 3H-buspirone and 3H-2-deoxyglucose after buspirone administration. Soc Neurosci Abstr 1985; 11: 1114.Google Scholar
  101. 101.
    Moring J, Alarotu P, Haukijarvi A, Ilvonen T, Karanen P, Kukkonen P, Ollinen M, Rasmussen M, Tamminen P, Lento H. Buspirone VS diazepam in treatment of anxiety in general practice. Viii World Congress of Psychiatry, Athens 1989; Abstract 1011.Google Scholar
  102. 102.
    Morton S, Lader MH. Buspirone treatment as an aid to benzodiazepine withdrawal. J Clin Psychopharmacol 1995; 9 (suppl 4): 331–335.CrossRefGoogle Scholar
  103. 103.
    Moss LE, Neppe VM, Drevets WC. Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1993; 13: 204–209.PubMedCrossRefGoogle Scholar
  104. 104.
    Murphy SM, Owen R, Tyrer P. Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks’ treatment with diazepam or buspirone. Br J Psychiatry 1989; 154: 529–534.PubMedCrossRefGoogle Scholar
  105. 105.
    Napoliello M.J. A study of buspirone coprescribed with antidepressants in 184 anxious ambulatory patients. Curr Ther Res 1986; 40: 917–923.Google Scholar
  106. 106.
    Neppe VM. High-dose buspirone in case of tardive dyskinesia (letter). Lancet 1989; 2: 1458.PubMedCrossRefGoogle Scholar
  107. 107.
    New JS. The discovery and development of buspirone: a new approach in the treatment of anxiety. Med Res Rev 1990; 10: 283–326.PubMedCrossRefGoogle Scholar
  108. 108.
    Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ. Review of the side-effect profile of buspirone. Am J Med 1986; 80 (suppl 3B): 17–21.PubMedCrossRefGoogle Scholar
  109. 109.
    Olajide D, Lader M. A comparison of buspirone, diazepam and placebo in patients with chronic anxiety states. J Clin Psychopharmacol 1987; 7: 148–152.PubMedCrossRefGoogle Scholar
  110. 110.
    Pato MT, Pigott TA, Hill JL, Grover GN, Bernstein S, Murphy DL. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1991; 148: 127–129.PubMedGoogle Scholar
  111. 111.
    Pecknold JC, Matas M, Howarth BG, Ross C, Swinson R, Vezeau C, Ungar W. Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Can J Psychiatry 1989; 34: 766–771.PubMedGoogle Scholar
  112. 112.
    Peroutka JJ. Selective interaction of novel anxiolytics with 5-hydroxy-tryptamine 1-A receptors. Biol Psychiatry 1985; 20: 971–979.PubMedCrossRefGoogle Scholar
  113. 113.
    Petracca A, Nisita C, Mcnair D, Melis G, Guerani G, Cassano GB. Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone. J Clin Psychiatry 1990; 51 (suppl 9): 31–39.PubMedGoogle Scholar
  114. 114.
    Pigott TA, L’Heureux F, Hilljl, Bihari K, Bernstein SE, Murphy DL. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12: 11–18.PubMedGoogle Scholar
  115. 114a.
    Pollicino AM, Spina E, Campo GM, Avenoso A, Caputi AP. Pharmacokinetic interactions between tricyclic antidepressants and other psychotropic drugs in depressed patients. Pharmacological Res 1992; 25: 210.CrossRefGoogle Scholar
  116. 115.
    PrivetrE TH, Hornsby RL, Myers RD. Buspirone alters alcohol drinking induced in rats by tetrahydropapaveroline injected into brain monoaminergic pathways. Alcohol 1988; 5: 147–152.CrossRefGoogle Scholar
  117. 116.
    Proulx J, Fontaine R, Dallal A. Buspirone in patients with atypical depression with panic attacks. Curr Ther Res 1991; 50: 127–132.Google Scholar
  118. 117.
    Rakel RE. Long-term buspirone therapy for chronic anxiety: a multicentre international study to determine safety. South Med J 1990; 83: 194–198.PubMedCrossRefGoogle Scholar
  119. 118.
    Ramchandran V, Thirunavukarasu M, Oke VG, Jha RJ, Navani SR, Bowalekar SK, Raghu CN. Comparative clinical evaluation of buspirone and diazepam in generalized anxiety disorders. Curr Ther Res 1990; 47: 502–510.Google Scholar
  120. 119.
    Rapoport DM, Greenberg HE, Goldring RM. Differing aspects of the anxiolytic agents buspirone and diazepam on control of breathing. Clin Pharmacol Ther 1991; 49: 394–401.PubMedCrossRefGoogle Scholar
  121. 120.
    Ratey JJ, Leveroni CL, Miller AC, Komry V, Gaffar K. Low-dose buspirone to treat agitation and maladaptive behavior in brain-injured patients. Two case reports (letter). J Clin Psychopharmacol 1992; 12: 362–364.PubMedCrossRefGoogle Scholar
  122. 121.
    Rickels K, Weisman K, Norstad N, Singer M, Stoltz D, Brown A, Danton J. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982; 43 (section 2): 81–86.PubMedGoogle Scholar
  123. 122.
    Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H. Longterm treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988; 45: 444–450.PubMedCrossRefGoogle Scholar
  124. 123.
    Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome (letter). Lancet 1989; 1: 777.PubMedCrossRefGoogle Scholar
  125. 124.
    Rickels K. Buspirone in clinical practice. J Clin Psychiatry 1990; 51 (suppl 9): 51–54.PubMedGoogle Scholar
  126. 125.
    Rickels K, Schweizer E. The clinical course and long-term management of generalized anxiety disorders. J Clin Psychopharmacol 1990; 10: 101S - 110S.PubMedCrossRefGoogle Scholar
  127. 126.
    Rickels K, Amsterdam JD, Clary C, Puzzuoli G, Schweizer E. Buspirone in major depression: a controlled study. J Clin Psychiatry 1991; 52: 34–38.PubMedGoogle Scholar
  128. 127.
    Ritchie EC, Bridenbaugh RH, Jabbari B. Acute generalized myoclonus following buspirone administration. J Clin Psychiatry 1988; 49: 242–243.PubMedGoogle Scholar
  129. 128.
    Robinson D, Napoliello MJ, Schenk J. The safety and usefulness of buspirone as an anxiolytic drug in elderly versus young patients. Clin Therapeutics 1988; 10: 740–746.Google Scholar
  130. 129.
    Robinson DS, Rickels K, Feighner J, Fabre LF JR., Gammans RE, Shrotriya RC, Alms DR, Andary JJ, Messina ME. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990; 10: 67S - 76S.PubMedCrossRefGoogle Scholar
  131. 130.
    Sakauye KM, Camp CJ, Ford PA. Effects of buspirone on agitation associated with dementia. Am J Geriatric Psychiatry 1993; 1: 82–84.CrossRefGoogle Scholar
  132. 131.
    Sass H, Wittchen H-U, Zaudig M. Diagnostisches und Statistisches Manual Psychischer Störungen. Göttingen: Hogrefe, 1996.Google Scholar
  133. 132.
    Sathanathan GL, Sanghvi I, Philipps N,Gershon S. Correlation between neuroleptic potential and stereotypy. Curr Ther Res 1975; 18: 701–705.Google Scholar
  134. 133.
    Scheibe G. Four-year follow-up in 40 outpatients with anxiety disorders buspirone versus lorazepam. Eur J Psychiat 1996; 10: 25–34.Google Scholar
  135. 134.
    Schweizer E, Rickels K, Luck! I. Resistance to the antianxiety effect of buspirone in patients with a history of benzodiazepine use. N Engl J Med 1986; 314: 719–720.PubMedCrossRefGoogle Scholar
  136. 135.
    Schweizer E, Rickels K. New and emerging clinical uses for buspirone. J Clin Psychiatry Monograph 1994; 12 (1); 46–55.Google Scholar
  137. 136.
    Schweizer E, Rickels K, Hassman H. A double-blind, placebo-controlled comparison of imipramine and buspirone in the treatment of major depression in the elderly in the community. Psychopharmacol Bull 1994; 30: 639.Google Scholar
  138. 137.
    Segal M. The action of serotonin in the rat hippocampal slice preparation J Physiol (Lond) 1980; 303: 423–429.Google Scholar
  139. 138.
    Seidel WF Cohen SA, Bliwise NG, Dement WC. Buspirone: an anxiolytic without sedative effect. Psychopharmacology 1985; 87: 371–373.CrossRefGoogle Scholar
  140. 139.
    Seppala T Aranko K, Mattila MJ, Shrotriya RC. Effects of alcohol on buspirone and lorazepam actions. Clin Pharmacol Ther 1982; 32: 201–207.CrossRefGoogle Scholar
  141. 140.
    Strand M, Hetta J, Rosen A, Sorensen S, MalmstrÖM R, Fabian C, Marits K, Vetterskog K, Liljestrand A-G, Hegen C. A doubleblind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 1990; 51 (suppl 9): 40–45.PubMedGoogle Scholar
  142. 141.
    Strauss A. Oral dyskinesia associated with buspirone use in an elderly woman. J Clin Psychiatry 1988; 49: 322–323.PubMedGoogle Scholar
  143. 142.
    Sussman N. The uses of buspirone in psychiatry. J Clin Psychiatry Monograph 1994; 12 (1): 3–19.Google Scholar
  144. 143.
    Tan SA, Tan LG. Beta-endorphin stimulatory effects of buspirone and clonidine. J Clin Res 1990; 38: 419A.Google Scholar
  145. 144.
    Tanquary J, Masan P. Paradoxical reaction to buspirone augmentation to fluoxetine. J Clin Psychopharmacol 1990; 10: 377.PubMedCrossRefGoogle Scholar
  146. 145.
    Taylor DP, Hyslop DK. Chronic administration of buspirone down-regulates 5-HT, receptor binding sites. Drug Develop Res 1991; 24: 93–105.CrossRefGoogle Scholar
  147. 146.
    TillerJwg. Psychomotor effects of buspirone, oxazepam and alcohol. Psychopharmacology 1988; 218 (suppl 96): Abstract 28. 33. 04.Google Scholar
  148. 147.
    TillerJwg, Dakis JA, Shaw JM. Short-term buspirone treatment in disinhibition with dementia (letter). Lancet 1988; 2: 510.PubMedCrossRefGoogle Scholar
  149. 148.
    Tollefson GD, Godes M, Montague-Clouse J, Lancaster SP, Garvey MJ. Buspirone: effects on prolactin and growth hormone as a function of drug level in generalized anxiety. J Clin Psychopharmacol 1989; 9: 132–136.PubMedCrossRefGoogle Scholar
  150. 149.
    Tollefson GD, Montague-Clouse J. The interrelationship of anxiety and alcoholism: a serotonin hypothesis. Family Practice Recertification 1989; 11 (suppl 9) 79–88.Google Scholar
  151. 150.
    Tollefson GD. 5-HT, a X of comorbid anxiety and alcoholism. Ann Clin Psychiatry 1990; 2: 287.CrossRefGoogle Scholar
  152. 151.
    Tompkins EC, Clemento AJ, Taylor DP, Perhach JL. Inhibition of aggressive behaviour in rhesus monkeys by buspirone. Res Corn Psycho) Psychiatr Behav 1980; 5: 337–352.Google Scholar
  153. 152.
    Tunnicliff G, Eison AS, Taylor DP (eds.). Buspirone. Mechanisms and Clinical Aspects. San Diego etc.: Academic Press, 1991.Google Scholar
  154. 153.
    Udelman HD, Udelman DL. Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. J Clin Psychiatry 1990; 51 (suppl 9): 46–50.PubMedGoogle Scholar
  155. 154.
    Yocca FD. Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT,A receptors. J Clin Psychopharmacol 1990; 10: 6S - 12S.PubMedCrossRefGoogle Scholar
  156. 155.
    Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL. Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry 1987; 44: 946–951.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Fachmedien Wiesbaden 1997

Authors and Affiliations

  • Hans-Peter Volz
    • 1
  1. 1.Klinik für PsychiatrieFriedrich-Schiller-Universität JenaJenaDeutschland

Personalised recommendations